Region: European Union

European patent litigation makes Oppo an EPO opposition target

Chinese mobile players are well acquainted with validity fights in the US and China, but Oppo and others increasingly find themselves under attack at the EPO

06 July 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of.

17 June 2021

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators

15 June 2021

French SPC rulings give first signs of Royalty Pharma’s impact

Paris Court of Appeal turns down three appeals over supplementary protection certificate rejections

12 April 2021

How the EPO’s latest CRISPR revocation affects the Cas9 landscape

Sigma-Aldrich’s patent loss could be a sign of things to come for several ongoing opposition proceedings

01 April 2021

Europe is seeing a boom in pharma and biotech patenting

A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest

25 March 2021

EU Teva investigation shows IP’s competition law issues aren’t limited to patent litigation settlements

Commission’s move against the Israeli generic is unprecedented, but could be a sign of things to come

18 March 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed

09 February 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

19 January 2021

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.

22 December 2020